| scholarly article | Q13442814 |
| P50 | author | Chi V. Dang | Q47824561 |
| P2093 | author name string | Xianxin Hua | |
| Lei Wang | |||
| Bryson W Katona | |||
| Guanghui Jin | |||
| Buddha Gurung | |||
| Paras Sharma | |||
| Smita Matkar | |||
| Abdul Bari Muhammad | |||
| Jennifer Liao | |||
| Shubin Gao | |||
| Xiang-Cheng Kong | |||
| P2860 | cites work | Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. | Q35204486 |
| PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis | Q35217174 | ||
| Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells | Q35816378 | ||
| Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation | Q35889621 | ||
| Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways | Q36378382 | ||
| Epigenetic therapy of cancer: past, present and future | Q36399557 | ||
| Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. | Q36638686 | ||
| Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. | Q36983065 | ||
| Control of c-myc regulation in normal and neoplastic cells. | Q37713213 | ||
| MYC as a regulator of ribosome biogenesis and protein synthesis | Q37718002 | ||
| FOXOs: signalling integrators for homeostasis maintenance | Q38074598 | ||
| Antagonism between FOXO and MYC Regulates Cellular Powerhouse | Q38102998 | ||
| Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers | Q40174208 | ||
| HER2 signaling enhances 5'UTR-mediated translation of c-Myc mRNA. | Q40557274 | ||
| Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs | Q42617375 | ||
| FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. | Q42636934 | ||
| FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons | Q42918105 | ||
| MLL2 mutation detection in 86 patients with Kabuki syndrome: a genotype-phenotype study. | Q50237955 | ||
| Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). | Q53985281 | ||
| Selective inhibition of BET bromodomains | Q24301009 | ||
| Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer | Q24307748 | ||
| Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth | Q24337427 | ||
| BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received | Q24610409 | ||
| Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma | Q24630610 | ||
| The PI3K pathway as drug target in human cancer | Q24632283 | ||
| Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Q27674674 | ||
| The super elongation complex (SEC) and MLL in development and disease | Q27692038 | ||
| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 | ||
| Cell signaling by receptor tyrosine kinases | Q27860474 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene | Q28201279 | ||
| Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells | Q28201813 | ||
| A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells | Q28282744 | ||
| Stressing the role of FoxO proteins in lifespan and disease | Q28303730 | ||
| MLL translocations, histone modifications and leukaemia stem-cell development | Q29615368 | ||
| Drug combination studies and their synergy quantification using the Chou-Talalay method | Q29617422 | ||
| The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis | Q29618035 | ||
| FOXO transcription factors at the interface between longevity and tumor suppression | Q29620472 | ||
| PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells | Q33945648 | ||
| c-Myc in breast cancer | Q34055118 | ||
| Discovery of Novel Forkhead Box O1 Inhibitors for Treating Type 2 Diabetes: Improvement of Fasting Glycemia in Diabetic db/db Mice | Q34132966 | ||
| Akt, FoxO and regulation of apoptosis | Q34173519 | ||
| Multiple histone methyl and acetyltransferase complex components bind the HLA-DRA gene | Q34304969 | ||
| AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity | Q34511038 | ||
| BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment | Q34632169 | ||
| A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer | Q34650878 | ||
| Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase | Q34720797 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 472-485 | |
| P577 | publication date | 2015-10-01 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis | |
| P478 | volume | 28 |
| Q90575658 | A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastoma |
| Q51102697 | BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells. |
| Q33557475 | BRD4 promotes p63 and GRHL3 expression downstream of FOXO in mammary epithelial cells |
| Q37283004 | Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS. |
| Q88360626 | Caddyshack therapeutics: overcoming glioblastoma adaptation |
| Q26752688 | Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting |
| Q61800257 | Dual regulation of by Myc is necessary during zebrafish retina regeneration |
| Q38975402 | Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies? |
| Q50056092 | Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer |
| Q38674456 | FOXO transcription factors in cancer development and therapy |
| Q90311439 | FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma |
| Q37697088 | FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc |
| Q55248424 | Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. |
| Q36787116 | Improving the reliability of peer-reviewed publications: We are all in it together |
| Q90192263 | Islet-specific Prmt5 excision leads to reduced insulin expression and glucose intolerance in mice |
| Q41098249 | Kinase inhibitors of HER2/AKT pathway induce ERK phosphorylation via a FOXO-dependent feedback loop |
| Q38812867 | Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms |
| Q38290097 | Menin and Daxx Interact to Suppress Neuroendocrine Tumors through Epigenetic Control of the Membrane Metallo-Endopeptidase |
| Q92490663 | Mission Possible: Advances in MYC Therapeutic Targeting in Cancer |
| Q38850598 | Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue |
| Q48126015 | Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis. |
| Q38765519 | Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma |
| Q90694884 | Role of BET Inhibitors in Triple Negative Breast Cancers |
| Q61817967 | Role of FoxO Proteins in Cellular Response to Antitumor Agents |
| Q88021277 | Targeting oncogenic Myc as a strategy for cancer treatment |
| Q90069521 | Targeting transcription factors in cancer - from undruggable to reality |
| Q53682037 | The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. |
| Q38890318 | The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness |
| Q92646352 | Ultrasound-mediated delivery of siESE complexed with microbubbles attenuates HER2+/- cell line proliferation and tumor growth in rodent models of breast cancer |
Search more.